All posts by medical

Documentary ‘Food Evolution’ turns to reason to discuss GMO controversy – Los Angeles Times

Calm, careful, potentially revolutionary, "Food Evolution" is an iconoclastic documentary on a hot-button topic. Persuasive rather than polemical, it's the unusual issue film that deals in counterintuitive reason rather than barely controlled hysteria.

As directed by Scott Hamilton Kennedy, "Food Evolution" wades into the controversy that makes the term GMO (genetically modified organisms) what Jon Stewart once called "the three most terrifying letters in the English language."

For what right-thinking citizen hasn't quailed at the thought of armies of artificially conceived zombie fruits and vegetables marching in lockstep under the command of monster corporation Monsanto until they take over the world.

As environmental activist Mark Lynas says, "its difficult to pay Monsanto a compliment. It's like praising witchcraft."

But taking as his theme a quote attributed to Mark Twain that posits, "It's easier to fool people than to convince them they have been fooled," filmmaker Kennedy wants us to consider the notion that much of what we feel about GMOs may be wrong.

Previously responsible for the splendid "OT: Our Town" and the Oscar-nominated "The Garden," about the plight of a 14-acre community garden in South Los Angeles, Kennedy is a veteran documentarian.

Here he's engaged the mellifluous voice of science celebrity Neil deGrasse Tyson as narrator and made sure to talk to people on both sides of the issue, partisans who, ironically, all have the same goal: safe, abundant food for everyone without the use of excessive toxic chemicals.

It is in fact the question of how to feed the staggering amount of people in the world more than 7 billion now, 9 billion by 2050 that was one of the stimuli that started Kennedy on this project. And he wants you to remember that trying to modify plants to emphasize desirable aspects is something farmers have been doing for a long time.

"Food Evolution" begins in Hawaii in 2013 when the big island's Hawaii County Council held hearings on whether to make the location into the world's first GMO-free zone.

That was ironic because Hawaii turns out to be a state with a major GMO success story, the rainbow papaya, which enabled papaya farming to come back from the dead after a devastating attack of disease in the 1990s.

While anti-GMO activists like Jeffrey Smith talk darkly of GMOs as "thoughtless, invasive species," the other side wrings its hands about pervasive doomsday tactics and distrust of scientific data.

"It's so much easier to scare people than reassure them," says writer Mark Lynas, with food authority Michael Pollan adding, "I don't believe fear-mongering has helped. I'm careful never to say GMOs are dangerous."

One statistic the film cites reveals the considerable gap 88% versus 37% between what scientists and laypeople say about whether GMOs are safe to eat.

"Food Evolution" takes time to carefully parse several issues that arise in the debate, like tumors in rats who eat GMO food (they get tumors no matter what they eat) and poundage versus toxicity in pesticide use.

The film also emphasizes that decisions made in the developed world can have global implications, exploring difficulties farmers in Uganda are having gaining access to the GMO bananas they want to combat decimation by disease.

"Food Evolution" certainly understands the larger factors that put GMO foods in the crosshairs: societal fury at corporate lying and greed, and distrust of Monsanto in particular as the developer of DDT and Agent Orange.

But finally the film is more troubled by the erosion of trust in science and by anti-GMO activists like Zen Honeycutt who says on camera that she trusts personal experiences of mothers more than the conclusions of scientists. As writer Lynas says, "If you throw science out, there is nothing."

Though it ultimately sides with the pro-GMO camp, "Food Evolution" makes some fascinating points about human behavior along the way, about how we don't make decisions based on facts as often as we think we do. This documentary may not change your mind, but it will make you consider what caused you to decide in the first place.

-------------

Food Evolution

Not rated

Running time: 1 hour, 32 minutes

Playing: Laemmle Monica, Santa Monica

See the most-read stories in Entertainment this hour

kenneth.turan@latimes.com

@KennethTuran

Excerpt from:
Documentary 'Food Evolution' turns to reason to discuss GMO controversy - Los Angeles Times

ObsEva Announces Presentations Related to its Assisted … – GlobeNewswire (press release)

June 29, 2017 07:01 ET | Source: ObsEva SA

Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART

Non-clinical results of OBE022 for PTL demonstrate both monotherapy/combination potential

Geneva, Switzerland and Boston, MA - 29 June 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced it will make presentations at the European Society of Human Reproduction and Embryology (ESHRE) 2017 Annual Meeting, taking place July 2-5 in Geneva, Switzerland. These presentations will include the following:

"We are pleased to have the opportunity to present to the medical community, these two sets of data from the development programs of two of our product candidates, nolasiban and OBE022." said Ernest Loumaye, MD, PhD, OBGYN, CEO and Co-Founder of ObsEva.

"The results of the IMPLANT study with nolasiban, previously reported, show a potential absolute improvement of about 10 percent, or greater in live birth rate in women undergoing assisted reproduction for infertility. This magnitude of improvement, if replicated in our ongoing, 760 patients, Phase 3, IMPLANT-2 clinical trial that we began in March of 2017, could have a significant impact on patients undergoing IVF as currently only about one out of three patients will go home with a baby after an embryo transfer.

The pharmacology data presented for OBE022 are also important as they not only indicate the potential of our compound to treat preterm labor as monotherapy but also displays additive effects with currently available treatments that have limited efficacy. We are utilizing these key data to design the Phase 2 program for OBE022 in pregnant women with preterm labor, which is scheduled to begin later this year."

About Assisted Reproductive Technology

Infertility affects about 10 percent of reproductive-aged couples, with approximately 1.6 million ART treatments (including IVF and ICSI) performed worldwide each year.

While the success of ART depends on multiple factors such as embryo quality and ET procedure, a successful pregnancy ultimately hinges on the receptivity of the uterus to accept embryo implantation. Uterine contractions at the time of ET, as well as suboptimal thickness of the uterine wall and blood flow to the uterus, may impair the implantation of the embryo.

About Nolasiban

Nolasiban (previously known as OBE001), is an oral oxytocin receptor antagonist with the potential to decrease uterine contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation, all of which may increase the chance of successful pregnancy and live-birth among patients undergoing ART. ObsEva licensed nolasiban from Merck-Serono in 2013 and retains worldwide commercial rights.

About Preterm Labor

Preterm labor, defined as the birthing process starting prior to 37 weeks of gestation, is a serious condition characterized by uterine contractions, cervical dilation and rupture of the fetal membranes that can lead to preterm birth. According to a study published in the Lancet in 2012, approximately 15 million babies were born before 37 weeks of gestation in 2010, accounting for 11.1% of all live births worldwide. Over 1 million children under the age of five died in 2013 worldwide due to preterm birth complications, and many infants who survive preterm birth are at greater risk for cerebral palsy, delays in development, hearing and vision issues, and often face a lifetime of disability. The rates of preterm births are rising in almost all countries with reliable data for preterm birth, and are associated with an immense financial impact to the global healthcare system.

To date, only treatments with limited efficacy or restrictive safety issues are available to treat preterm labor. Inthe United States, recommended first-line tocolytic treatments (medications that inhibit labor) include beta-adrenergic receptor agonists, calcium channel blockers, or NSAIDs, which are used for short-term prolongation of pregnancy (up to 48 hours) to allow for the administration of antenatal steroids (e.g. betamethasone). Magnesium sulfate, used for fetal neuroprotection can also be used (up to 48 hours) to inhibit acute preterm labor. Approved tocolytic treatments inEuropeinclude beta-adrenergic agonists, which carry severe maternal cardiovascular risks, and intravenous infusions of atosiban (an oxytocin receptor antagonist).

While prostaglandin inhibitors (NSAIDs) have been shown to be effective for inhibiting preterm labor, use of such drugs is limited, due to the threat of serious and sometimes life-threatening side effects in the fetus. Such side effects may include kidney function impairment, premature constriction of the blood vessel connecting the pulmonary artery and the descending aorta in a developing fetus, and higher risk of thrombosis of the intestinal arteries (a condition called necrotizing enterocolitis).

About OBE022 andPGF2alpha

ObsEvais developing OBE022, a potential first-in-class, once daily, oral and selective prostaglandin F2alpha receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin inhibitors (NSAIDs). PGF2alpha is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies,ObsEvahas observed that OBE022 markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with prostaglandin inhibitors such as indomethacin. ObsEva licensed OBE022 from Merck-Serono in 2015 and retains worldwide commercial rights.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit http://www.ObsEva.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva's current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and related interactions with regulatory bodies, ObsEva's reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva's Annual Report on Form 20-F for the year ended December 31, 2016, and other filings ObsEva makes with the SEC from time to time. These documents are available on the Investors page of ObsEva's website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

###

Media Contact: Liz Bryan Spectrum Science lbryan@spectrumscience.com + 1 202-955-6222 x2526

Company Contact: CEO Office Contact Delphine Renaud delphine.renaud@obseva.ch +41 22-552-1550

Investor Contact Mario Corso Senior Director, Investor Relations mario.corso@obseva.com +1 781-366-5726

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/0407f96e-505f-4b8f-a8df-6bd9c4023e6d

Related Articles

Visit link:
ObsEva Announces Presentations Related to its Assisted ... - GlobeNewswire (press release)

Scientists Manipulate ‘Signaling’ Molecules to Control Cell Migration – Bioscience Technology

Johns Hopkins researchers report they have uncovered a mechanism in amoebae that rapidly changes the way cells migrate by resetting their sensitivity to the naturally occurring internal signaling events that drive such movement. The finding, described in a report published online March 28 in Nature Cell Biology, demonstrates that the migratory behavior of cells may be less hard-wired than previously thought, the researchers say, and advances the future possibility of finding ways to manipulate and control some deadly forms of cell migration, including cancer metastasis.

"In different tissues inside the body, cells adopt different ways to migrate, based on their genetic profile and environment," says Yuchuan Miao, a graduate student at the Johns Hopkins University School of Medicine and lead author of the study. "This gives them better efficiency to perform specific tasks." For example, white blood cells rhythmically extend small protrusions that allow them to squeeze through blood vessels, whereas skin cells glide, like moving fans, to close wounds.

On the other hand, Miao notes, uncontrolled cell migration contributes to diseases, including cancer and atherosclerosis, the two leading causes of death in the United States. The migration of tumor cells to distant sites in the body, or metastasis, is what kills most cancer patients, and defective white blood cell migration causes atherosclerosis and inflammatory diseases, such as arthritis, which affects 54 million Americans and costs more than $125 billion annually in medical expenditures and lost earnings.

Because cells migrate in different ways, many drugs already designed to prevent migration work only narrowly and are rarely more than mildly effective, fueling the search for new strategies to control migratory switches and treat migration-related diseases, according to senior author Peter Devreotes, Ph.D., a professor and director of the Department of Cell Biology at the Johns Hopkins University School of Medicines Institute for Basic Biomedical Research.

People have thought that cells are typed by the way they look and migrate; our work shows that we can change the cell's migrating mode within minutes, adds Devreotes.

For the new study, Devreotes and his team focused on how chemical signaling molecules activate the motility machinery to generate protrusions, cellular feet that are a first step in migration. To do this, they engineered a strain of Dictyostelium discoideum, an amoeba that can move itself around in a manner similar to white blood cells. The engineered amoebae responded to the chemical rapamycin by rapidly moving the enzyme Inp54p to the cell surface, where it disrupted the signaling network. The cells also contained fluorescent proteins, or markers, that lit up and showed researchers when and where signaling molecules were at work.

Experiments showed that the engineered cells changed their migration behavior within minutes of Inp54p recruitment. Some cells, which the researchers termed oscillators, first extended protrusions all around the cell margins and then suddenly pulled them back again, moving in short spurts before repeating the cycle. Fluorescent markers showed that these cycles corresponded to alternating periods of total activation and inactivation, in contrast to the small bursts of activity seen in normal cells.

Other cells began to glide as fans, with a broad zone of protrusions marked by persistent signaling activity.

Devreotes describes the signaling behavior at the cell surface as a series of waves of activated signaling molecules that switch on the cellular motility machinery as they spread. In their normal state, cells spontaneously initiated signaling events to form short-lived waves that made small protrusions.

In contrast, oscillators had faster signaling waves that reached the entire cell boundary to generate protrusions before dying out. Fans also showed expanded waves that continually activated the cell front without ever reaching the cell rear, resulting in wide, persistent protrusions.

The scientists say their experiments show that the cell movement changes they saw resulted from lowering the threshold level of signaling activity required to form a wave. That is, cells with a lower threshold are more likely to generate waves and, once initiated, the activation signals spread farther with each step.

Devreotes says the teams experimental results offer what appears to be the first direct evidence that waves of signaling molecules drive migratory behavior. Previously, his laboratory showed a link between signaling and migration, but had not specifically examined waves.

In further experiments, Devreotes and his team found that they could recruit different proteins to shift cell motility, suggesting, he says, that altering threshold is a general cell property that can change behaviorno matter how cells migrate. His team was also able to restore normal motility to fans and oscillators by blocking various signaling activities, suggesting new targets for drugs that could be designed to control migration.

Devreotes cautions that what happens in an amoeba may not have an exact counterpart in a human cell, but studies in his lab suggest that something like the wave-signaling mechanism they uncovered operates in human cells as well.

The bottom line, says Miao, is that we now know we can change signaling wave behavior to control the types of protrusions cells make. When cells have different protrusions, they have different migratory modes. When we come to understand the essential differences between cells migratory modes, we should have better ways to control them during disease conditions.

Read more:
Scientists Manipulate 'Signaling' Molecules to Control Cell Migration - Bioscience Technology

Norris Cotton Cancer Center Announces New Chief From NY – Valley News

Lebanon Dartmouth-Hitchcock and Geisel School of Medicine at Dartmouth announced the hiring of a new leader for Norris Cotton Cancer Center in a release on Thursday.

Dr. Steven Leach, 57, a surgical oncologist, comes to Norris Cotton from the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center in New York.

His new position will include overseeing cancer research at Dartmouth and the Geisel School of Medicine, as well as the cancer care that is provided throughout Dartmouth-Hitchcocks health system.

Both D-H and Dartmouth officials welcomed Leach in Thursdays release.

Dr. Leach is a world renowned pancreatic cancer specialist with significant interest in the biology, models, and mechanisms of cancer development and in genomic research to perform sequencing and analysis of the cell types involved in human pancreatic cancer, said Dr. James Weinstein, D-Hs outgoing chief executive.

He will lead Dartmouth-Hitchcock and the Cancer Center into a new era of research and discovery at the molecular level that will benefit patients for generations to come.

At Geisel, where Leach will hold the title of Preston T. and Virginia R. Kelsey Distinguished Chair in Cancer, the schools dean Dr. Duane Compton said, I look forward to working with (Leach) to grow our cancer-related research programs across Dartmouth and build on our outstanding cancer clinical care through Dartmouth-Hitchcock.

Leach will be the first permanent director of the center since former director Mark Israel left the post last fall. Chris Amos, the chairman of Geisels biomedical data science department, has served as interim director since October.

Leach was drawn to the position at Norris Cotton because of the opportunity to work throughout the region in with a multidisciplinary focus in collaboration with researchers at Geisel, D-H and Dartmouth College to push scientific envelopes, he said, in a phone interview on Thursday afternoon.

While hes in the midst of transitioning to the center, Leach said hes deeply involved in a crash course in all things Dartmouth ... issues and opportunities.

Leach comes to the job amid controversy about how funds raised for cancer research were spent. In October, Israel filed a lawsuit against Dartmouth-Hitchcock, alleging that he was ousted in an act of illegal retaliation after he objected to the diversion of $6 million raised for cancer research, including $1.6 million raised from The Prouty, Norris Cottons signature fundraising event.

D-H subsequently asked Grafton County Superior Court Judge Lawrence A. MacLeod Jr. to move the case to arbitration and, in April, MacLeod agreed. MacLeod has not yet ruled on a motion Israel filed last month seeking permission to file an amended suit.

Separately, Thomas Donovan, the director of the Charitable Trusts Unit in the New Hampshire Attorney Generals Office, concluded in January that D-H had not violated the law in 2015 when it spent money from donors on salary, equipment and occupancy costs associated with research.

And in February, cancer center officials announced in a Valley News op-ed a pledge that supporters donations will be used only for activities related to research and patient care, as well as governance guidelines written into a new agreement between D-H and Dartmouth College that clarify the authority of the centers director, who is a joint employee of both organizations.

For his part, Leach said he is aware of the issues relating to the way these funds were spent, but he has full confidence in the leadership of the two organizations moving forward.

Im confident in the leadership there that weve got everything in place, he said.

Leach himself is an enthusiastic fundraiser and he looks forward to connecting with people to tell the story of the wonderful science thats being done at Dartmouth.

(Its) something I really enjoy, he said.

Leach brings experiences as a researcher, teacher and clinician to the position.

He has served as the director for Sloan Ketterings pancreatic research center since it opened in 2014. He is also a professor of surgery at Weill Cornell Medical College of Cornell University.

Prior to coming to New York, Leach worked at Johns Hopkins University where he was a professor of pancreatic cancer research, surgery, oncology and cell biology, and chief of the division of surgical oncology.

At heart, Leach said he is a physician scientist, who began as a surgeon operating on all kinds of cancer patients and moved into research, teaching and administrative roles.

Leach holds a bachelors degree in biology from Princeton University and a medical degree from Emory University. He did a residency in general surgery and a post-doctoral research fellowship at Yale University, and a surgical oncology fellowship at the University of Texas MD Anderson Cancer Center.

He recently completed a term on Princetons board of trustees and serves as chairman of the Pancreatic Cancer Action Networks Scientific and Medical Advisory Board.

He expects to start the new position in September, but will be in the Upper Valley biking 50 miles in The Prouty on July 8.

Im looking forward to coming up and experiencing The Prouty, Leach said.

Nora Doyle-Burr can be reached at ndoyleburr@vnews.com or 603-727-3213.

Read the rest here:
Norris Cotton Cancer Center Announces New Chief From NY - Valley News

Inside Project Viking: Anatomy of deal to float AIB – Irish Times

Shortly after midnight last Friday, Ann Nolan, deputy head of the Department of Finance, and two officials working on AIBs flotation hailed a taxi from the Dawson Street base of stockbrokers Davy in Dublin to the home of Paschal Donohoe.

The Finance Minister of just one week had been on standby in Phibsborough all evening, as department officials, investment bankers from Deutsche Bank, Bank of America Merrill Lynch and Davy, divvied out AIB shares to more than 230 international fund managers and 6,500 small investors who had sought access to Europes largest initial public offering (IPO) so far this year.

The Minister made us a cup of tea and we spent an hour with him, said Des Carville, head of the Department of Finances banking unit and official in charge of the flotation, who shared the taxi ride. He had plenty of questions and we walked him through where we were with the deal and the final list of investors.

Armed with Mr Donohoes approval and signature on various documents, the trio headed back to the deals nerve centre in Davy, to finalise paperwork, paving the way for AIB to return that morning to the main stock markets in Dublin and London after a 7-year absence.

It was after 2am before all assembled, including AIB chief executive Bernard Byrne and his chief financial officer Mark Bourke, who had flown in from London that evening, headed home. They wouldnt get much sleep.

Project Viking, two years in the planning, culminated at 7am that morning when the Government confirmed it had sold an initial 25 per cent stake in the most expensive surviving Irish bank to bail out during the crisis, raising 3 billion. As the shares rose by as much as 7.7 per cent in early trading in Dublin, the investment banks underwriting the deal exercised an option to buy a further 3.8 per cent stake from the State and placed it on the market, raising a further 400 million for the exchequer.

The bank that floated was a very different animal to the one that was seized by the State two days before Christmas in 2010 to avert its collapse under the weight of mounting bad debts.

To limit its taxpayer bailout to 20.8 billion between 2009 and 2011, AIB was forced to sell billions of euros of assets including its profitable Polish unit, Bank Zachodni WBK, and 24 per cent stake in US lender M&T Bank and inflict 5 billion of losses on holders of its riskiest, subordinated bonds.

As a ward of the State, the company slashed thousands of jobs and put as many as 2,000 staff into a loan-restructuring unit to work through and restructure a mountain of soured loans, which topped 29 billion in 2013, over a third of its entire loan book at the time.

The fruits of the efforts were apparent in early March, when the group reported its impaired loans had fallen to 9 billion, pre-tax profits came to 1.7 billion for 2016 and that it had sufficient capital in reserve to give regulators comfort for AIB to pay a 250 million dividend.

The market reaction to the full-year 2016 results were very important we assessed it very closely, said Mr Carville. The icing on the cake was getting the dividend. That was very material in terms of AIBs valuation and also [potential investors in] the bank. Suddenly the guys who really like to have income in their investments were very interested in this as well.

While the then minister for finance, Michael Noonan, stuck to a script that he saw two windows to float AIB this year in May/June or in the autumn officials working on the deal were emboldened enough by the London reception and general market conditions to start working towards a deal in early May.

British prime minister Theresa Mays move on April 18th to call a snap election on June 8th put paid to such plans. An announcement on a deal was notionally put back until the end of the month, meaning it would price towards the end of June, leaving investors plenty of time to digest the UK vote.

But no one had counted on a second UK surprise, when it became clear in the early hours of June 9th that Theresa May had failed to return an expected landslide victory and now found herself short of a parliamentary majority 10 days before crucial Brexit talks were due to start.

As markets absorbed the shock outcome, AIBs chief executive, Mark Bourke popped out of his office at the banks headquarters in Ballsbridge in Dublin at 8am to meet Des Carville in a nearby coffee shop. Matters were out of their control at this stage, so they decided to keep a watching a brief on European markets.

At mid-morning, bankers from Deutsche Bank, Bank of America Merrill Lynch and Davy, who were leading the 3 billion share sale, as well as the Department of Finances independent advisers, Rothschild, gathered in Dublin for a pre-scheduled meeting on how the deal was going down.

While feedback from the nine firms working on the deal, including Citigroup, Goldman Sachs, Goodbody, JP Morgan, UBS and Investec and whose analysts had carried out 1,500 meetings with potential investors in less than two weeks, was upbeat, the UK result had thrown a spanner in the works.

By the time the markets had closed on Monday, advisers on the deal felt that issuance of the price range and prospectus could actually be brought forward. Michael Noonan made the call that evening to proceed immediately, setting an initial price range for the shares being sold at between 3.90 and 4.90 each. It would be his last major decision as finance minister, capping six years in office.

At AIB Bankcentre in Ballsbridge, a team in a fourth-floor room in the investor relations department where a wall carried four clocks displaying times in Dublin, Los Angeles, New York and Hong Kong kicked into action, mobilising three teams to market the bank globally.

Robert Mulhall, head of AIBs Irish retail and commercial banking division, was already on the west coast of the US, having attended a Google executive conference in Silicon Valley that weekend, according to sources. Group director of finance and investor relations Myles OGrady flew out to meet him on the Tuesday and begin that leg of the roadshow.

In Dublin, Bernard Byrne, Mark Bourke and investor relations managers Niamh Hore and Rose ODonovan kicked off in Dublin meeting fund managers before heading to London, where they were joined by group chief operating officer Tomas OMidheach.

Meanwhile, group treasurer Donal Galvin, chief economist Oliver Mangan and Janet McConkey of investor relations flew to Singapore to begin the courting of Asian investors before returning to Europe, where they met up with Colin Hunt, head of wholesale and institutional banking.

Within 24 hours of the initial pricing range being set, the investment banks decided to prod potential investors by putting out a notification that they had received enough orders to cover all the shares being sold.

On June 21st, Paschal Donohoe signed off on a narrowing of the price range to between 4.30 and 4.50, and the following morning he allowed managers of the transaction to send out a warning an hour before the order books closed at noon that any bids below 4.40 risked being cut out of the deal.

With the price of the transaction set at 4.40, the three main firms managing the process assembled at Davy at 5pm on June 22nd with Department of Finance officials, including Scott Rankin, Joseph Cummins, Ronan Heavey, Gary Hynds and Elaine McNamara and AIBs Bernard Byrne to go through the allocation of shares to investors.

Some 6,500 small investors would receive 10 per cent of the shares on offer. About 30 per cent of the institutional investors who sought to get on board were refused any shares as they hadnt met analysts or management during the process.

Wed never heard of them. The majority of them, if not all of them, were just momentum traders, who would sell immediately if the stock went up, said Mr Carville. It would have been close to midnight before the allocations were completed.

US investors snapped up a quarter of the shares being sold, with UK-based institutions accounting for a third, with the remainder handed out to investors across Europe and the rest of the world.

The reception in continental Europe wasnt quite as good as elsewhere, said an investment banking source close to the deal. There still is a bit of scepticism in Europe about Irish banks and, indeed, the banking sector in general.

While non-performing loans have come down sharply across Irish banks over the past four years, as the economy rebounded from the crash and lenders restructured problem loans at pace, almost 16 per cent of loans across the sector remain impaired, according to Government figures. Thats three times the European average.

Still, AIB shares jumped 4.5 per cent on the opening of trade in Dublin at 8am last Friday, to 4.60, before rising as much as 7.7 per cent.

Im absolutely satisfied that the 4.40 price was right, said Des Carville, a former corporate financier with Davy, who was hired by the department in 2013 to head the management of the States stakes in bailed-out banks. We lost quite a number of investors at that price, as it was just too expensive for them. Thats the acid test. But, importantly, we also kept equally high-quality investors at that level. But once you went above 4.40, the quality fell off a cliff. Mr Carvilles first congratulatory text of the day came within minutes of trading getting under way, from Richie Boucher, the outgoing chief executive of Bank of Ireland, in which taxpayers continue to own a 14 per cent stake.

He was followed shortly by Jeremy Masding, chief executive of Permanent TSB, which is 75 per cent State owned.

After that, it was around to Doheny & Nesbitts on Baggot Street for 18 members of the departments banking team for a quick celebratory breakfast.

Mr Byrne sent a short video message by email to AIBs 10,400 staff less than half the banks workforce before the crash shortly after 7am.

This marks a really satisfactory conclusion to what has been a long, difficult and complicated process, he said. Everyone should be very proud of what this investment means.

Now we are in a position where the bank that weve been building, the bank that weve asked everyone to believe in is clearly one that investors believe they can invest in.

Before the IPO, AIB had repaid only 3.3 billion of capital pumped into the bank. However, the State had also recouped an additional 3.5 billion in cash from AIB, the most costly bank rescue behind Anglo Irish Bank, by way of interest payments on bailout bonds and guarantee fees.

Mr Donohoe told journalists last week that he was confident the State would recover all of the money injected into the bank, over time. Still, by Michael Noonans previous admission, it could take up to a decade before taxpayers are fully rid of AIB shares.

Meanwhile, Nolan, a key figure on the States bailout and restructuring of the banking sector during the crisis, signalled yesterday she plans to retire at the end of next month

Continue reading here:
Inside Project Viking: Anatomy of deal to float AIB - Irish Times

Anatomy of a Goal: How Cristian Roldan’s defense, Clint Dempsey’s movement led to equalizer against Portland – SoundersFC.com

The Seattle Sounders stole a dramatic road point against the Portland Timbers last Sunday in what was their arguably their best effort of the season. Down a man and a goal for the entire second half, substitute Clint Dempsey headed home an equalizer in the 94th minute to stun Providence Park.

The entire sequence, though Roman Torres pinpoint cross to Dempsey, Dempseys towering header and the unlikeliest of goals did not matriculate from nothing. What led to the Sounders game-tying tally was a seemingly inconspicuousdefensive play by Cristian Roldan on Dairon Asprilla.

Nearing the end of the 93rd minute, the Timbers cleared the ball from their own 18-yard-box and found Asprilla in open space on the left side of the pitch. Desperate for an equalizer, the Sounders had thrown almost everyone forward, which in turnleft Asprilla and Fanendo Adi in a 2-on-2 situation with Nouhou and a retreating Roldan.

Rather than sprinting back aimlessly, Roldan defended with purpose, coming in goalside on an angle behind Asprilla.

When Asprilla finally receivedthe ball, his options were limited because of Roldans positioning. Asprilla turnedand facedbackward, attempting to hold up the ball in search of a teammate. He never gets the chance to find one.

Hanging on Asprillas right shoulder, Roldan reached his left leg around Asprilla and poked the ball away. Roldan then quickly led the Sounders back in the ascendancy and left an off-balanced Asprilla on the Providence Park turf.

What Roldans stalwart defending did was not only unbalance Asprilla, but the entire Portland team that had just begun pushing forward to clear its own end in anticipation ofan attack. Roldan recognizedthis and pickedout Osvaldo Alonso wide open in the center of the park.

The Timbers were scrambling at this point, but they were not totally undone until Dempsey set up his own attempt on goal with a simple off-the-ball run that very few players would have had the wherewithal to make.

Alonso hadthe ball and was looking for Dempsey to his right, but he was being trailed by Diego Chara with Ben Zemanski blocking Alonsos passing lane.

Rather than stay put or check back to Alonso, Dempsey saw a pocket of space behind Zemanski and to Zemanskisright. Dempsey ran toward it and by doing so, pulledChara out of position and forcedZemanski to lean in that direction, opening a giant passing lane for Alonso to find the late run ofTorres.

Another reason why Dempsey was able to able to rise and meet Torres cross without much resistance was becausehis run into the box was unimpeded. When the ball swungwide to Torres, Chara shifted his attentionand left Dempsey free to roam.

This left the two Timbers center backs with very little time to communicate on whose responsibility it was to guard Dempsey. By the time they figured it out, Dempsey was jumping over Amobi Okugo and redirecting Torres cross past a helpless Jake Gleeson in goal.

Dempseys finish was a fantastic one and is another example of why hes on the brink of becoming the United States all-time leading goalscorer, but it would not have happened without his subtle off-the-ball movement and a little help from the Swiss army knife that is Cristian Roldan. Goals dont happen in a vacuum. Singular moments of brilliance are always preceded by several small but vital plays, and the Sounders proved that yet again on Sunday.

View post:
Anatomy of a Goal: How Cristian Roldan's defense, Clint Dempsey's movement led to equalizer against Portland - SoundersFC.com

Want to understand Russia’s economy? Try reading Tolstoy. – Marketplace.org

ByDavid Brancaccio

June 28, 2017 | 5:00 AM

Economics is fundamentally the study of human behavior. Yes, it's steeped in equations and math, but some argue it's equally based on philosophy and the arts. A new book by Morton Schapiro and Gary Saul Morson looks at what insight economists can gain from reading classic literature.

Northwestern University President Morton Schapiro joined Marketplace Morning Report host David Brancaccio to discuss Cents and Sensibility: What Economics Can Learn from the Humanities.

Click on the audio player above to hear their conversation.

View post:
Want to understand Russia's economy? Try reading Tolstoy. - Marketplace.org

A leading Silicon Valley engineer explains why every tech worker needs a humanities education – Quartz

In 2005, the late writer David Foster Wallace delivered a now-famous commencement address. It starts with the story of the fish in water, who spend their lives not even knowing what water is. They are naively unaware of the ocean that permits their existence, and the currents that carry them.

The most important education we can receive, Wallace goes on to explain, isnt really about the capacity to think, but rather about the choice of what to think about. He talks about finding appreciation for the richness of humanity and society. But it is the core concept of meta-cognition, of examining and editing what it is that we choose to contemplate, that has fixated me as someone who works in the tech industry.

As much as code and computation and data can feel as if they are mechanistically neutral, they are not. Technology products and services are built by humans who build their biases and flawed thinking right into those products and serviceswhich in turn shapes human behavior and society, sometimes to a frightening degree. Its arguable, for example, that online medias reliance on clickbait journalism, and Facebooks role in spreading fake news or otherwise sensationalized stories influenced the results of the 2016 US presidential election. This criticism is far from outward-facing; it comes from a place of self-reflection.

I studied engineering at Stanford University, and at the time I thought that was all I needed to study. I focused on problem-solving in the technical domain, and learned to see the world through the lens of equations, axioms, and lines of code. I found beauty and elegance in well-formulated optimization problems, tidy mathematical proofs, clever time- and space-efficient algorithms. Humanities classes, by contrast, I felt to be dreary, overwrought exercises in finding meaning where there was none. I dutifully completed my general education requirements in ethical reasoning and global community. But I was dismissive of the idea that there was any real value to be gleaned from the coursework.

Upon graduation, I went off to work as a software engineer at a small startup, Quora, then composed of only four people. Partly as a function of it being my first full-time job, and partly because the company and our producta question and answer sitewas so nascent, I found myself for the first time deeply considering what it was that I was working on, and to what end, and why.

As my teammates and I were building Quora, we were also simultaneously defining what it should be, whom it would serve, and what behaviors we wanted to incentivize amongst our users.I was no longer operating in a world circumscribed by lesson plans, problem sets and programming assignments, and intended course outcomes. I also wasnt coding to specs, because there were no specs. As my teammates and I were building the product, we were also simultaneously defining what it should be, whom it would serve, what behaviors we wanted to incentivize amongst our users, what kind of community it would become, and what kind of value we hoped to create in the world.

]I still loved immersing myself in code and falling into a state of flowthose hours-long intensive coding sessions where I could put everything else aside and focus solely on the engineering tasks at hand. But I also came to realize that such disengagement from reality and societal context could only be temporary.

The first feature I built when I worked at Quora was the block button. Even when the community numbered only in the thousands, there were already people who seemed to delight in being obnoxious and offensive. I was eager to work on the feature because I personally felt antagonized and abused on the site (gender isnt an unlikely reason as to why). As such, I had an immediate desire to make use of a blocking function. But if I hadnt had that personal perspective, its possible that the Quora team wouldnt have prioritized building a block button so early in its existence.

Our thinking around anti-harassment design also intersected a great deal with our thinking on free speech and moderation. We pondered the philosophical questionalso very relevant to our productof whether people were by default good or bad. If people were mostly good, then we would design the product around the idea that we could trust users, with controls for rolling back the actions of bad actors in the exceptional cases. If they were by default bad, it would be better to put all user contributions and edits through approvals queues for moderator review.

We pondered the philosophical questionalso very relevant to our productof whether people were by default good or bad.We debated the implications for open discourse: If we trusted users by default, and then we had an influx of low quality users (and how appropriate was it, even, to be labeling users in such a way?), what kind of deteriorative effect might that have on the community? But if we didnt trust Quora members, and instead always gave preference to existing users that were known to be high quality, would we end up with an opinionated, ossified, old-guard, niche community that rejected newcomers and new thoughts?

In the end, we chose to bias ourselves toward an open and free platform, believing not only in people but also in positive community norms and our ability to shape those through engineering and design. Perhaps, and probably, that was the right call. But weve also seen how the same bias in the design of another, pithier public platform has empowered and elevated abusers, harassers, and trolls to levels of national and international concern.

At Quora, and later at Pinterest, I also worked on the algorithms powering their respective homefeeds: the streams of content presented to users upon initial login, the default views we pushed to users. It seems simple enough to want to show users good content when they open up an app. But what makes for good content? Is the goal to help users to discover new ideas and expand their intellectual and creative horizons? To show them exactly the sort of content that they know they already like? Or, most easily measurable, to show them the content theyre most likely to click on and share, and that will make them spend the most time on the service?

It worries me that so many of the builders of technology today are people who havent spent time thinking about these larger questions.Ruefullyand with some embarrassment at my younger selfs condescending attitude toward the humanitiesI now wish that I had strived for a proper liberal arts education. That Id learned how to think critically about the world we live in and how to engage with it. That Id absorbed lessons about how to identify and interrogate privilege, power structures, structural inequality, and injustice. That Id had opportunities to debate my peers and develop informed opinions on philosophy and morality. And even more than all of that, I wish Id even realized that these were worthwhile thoughts to fill my mind withthat all of my engineering work would be contextualized by such subjects.

It worries me that so many of the builders of technology today are people like me; people havent spent anywhere near enough time thinking about these larger questions of what it is that we are building, and what the implications are for the world.

But it is never too late to be curious. Each of us can choose to learn, to read, to talk to people, to travel, and to engage intellectually and ethically. I hope that we all do soso that we can come to acknowledge the full complexity and wonder of the world we live in, and be thoughtful in designing the future of it.

Follow Tracy on Twitter. Learn how to write for Quartz Ideas. We welcome your comments at ideas@qz.com.

Visit link:
A leading Silicon Valley engineer explains why every tech worker needs a humanities education - Quartz

Ovation Fertility Presents Reproductive Technology Advancements at Renowned ESHRE Conference July 2 – 5 in … – PR Web (press release)

Ovation Fertility Chief Executive Officer Nate Snyder

LOS ANGELES, CA (PRWEB) June 28, 2017

Ovation Fertility continues to maintain its presence in the international market with three research projects accepted for presentation at the 33rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE). Nearly 10,000 participants including some of the worlds top thought leaders in reproductive medicine are expected to attend the event July 2-5 in Geneva, Switzerland.

Ovation Fertility topics include advancements in embryo biopsy techniques and frozen embryo storage, plus advantages of preimplantation genetic screening.

ESHRE is selective about the research it accepts for presentation, and our presence speaks to the expertise of our scientists and partner physicians, says Ovation Fertility Chief Executive Officer Nate Snyder. We are honored to join other top minds at the international level who are bringing about global advancements and innovations in technology that make families possible for people who have struggled with infertility.

Presentations at Conference

Ovation Fertility will present three posters on its current research:

1.Differential human blastocyst vitrification: A randomized comparative trial assessing solution and device treatments under varying cooling/warming conditions

The vitrification, or freezing, of human embryos for storage has evolved into a highly reliable and efficient process in most assisted reproductive technology laboratories worldwide. Over the past several years, Ovation Fertility Newport Beach Lab Director Mitchel C. Schiewe, Ph.D., has strived to better understand the physical and chemical relationships of vitrification treatments using a re-vitrification model to define thresholds of tolerance for post-warming survival/viability.

Authors: Mitchel C. Schiewe, Ph.D.; Cherie Gibbs; RaeAnne vanTol; Kelley Waggoner; Kay Howard; Julie Howard; Amy Jones; Melanie Freeman, Ph.D.; and Shane Zozula

2.Does the blastocyst biopsy technique affect aneuploidy rates?

This study looked into the inherent variables associated with the blastocyst biopsy procedure, and whether they influence aneuploidy, or chromosomal abnormality, rates. Conclusions showed that embryo quality and the day of development had no significance when conducting a difficult biopsy.

Authors: John Whitney; Robert E. Anderson, M.D., (Southern California Center for Reproductive Medicine); Cecelia Rios; Nancy Nugent; Shane Zozula; and Mitchel C. Schiewe, Ph.D.

3.Lessons learned from over 1,100 preimplantation genetic screening (PGS) cycles: outcome analysis

Ovation Fertility researchers looked at relevant clinical outcome percentages for blastocyst development and aneuploidy in women using preimplantation genetic screening in conjunction with age groups. Cycles generating at least one euploid, or chromosomally normal, blastocyst occurred 89% of the time for patients younger than 38; 59% for patients 38 years or older; and 100% occurrence using an egg donor.

Authors: Robert E. Anderson M.D., (Southern California Center for Reproductive Medicine); Mitchel C. Schiewe, Ph.D.; and John Whitney

About Ovation Fertility Ovation Fertility Founded in 2015 by a coalition of thought-leading reproductive endocrinologists and scientists, Ovation Fertility is a national fertility service provider offering a suite of state-of-the-art assisted reproductive technology services to aspiring parents, including embryology, andrology and genetic testing as part of the in vitro fertilization process. Ovation Fertility partners with physicians who are committed to reducing the average cost of a live birth through IVF by advancing industry standards in fertility treatment. For more information, visit http://www.ovationfertility.com.

Share article on social media or email:

See original here:
Ovation Fertility Presents Reproductive Technology Advancements at Renowned ESHRE Conference July 2 - 5 in ... - PR Web (press release)

Anatomy | Definition of Anatomy by Merriam-Webster

noun anatomy -na-t-m

noun anatomy -na-t-m

1 : a science that has to do with the structure of living things

2 : the structural makeup especially of a person or animal the anatomy of the cat

noun anatomy -nat--m

1: a branch of morphology that deals with the structure of organismscompare physiology 1

2: a treatise on anatomic science or art

3: the art of separating the parts of an organism in order to ascertain their position, relations, structure, and function : dissection

4: structural makeup especially of an organism or any of its parts

Excerpt from:
Anatomy | Definition of Anatomy by Merriam-Webster